« Previous
Next »
Journal of Clinical Densitometry
Volume 13, Issue 1
, Pages
56-62
, January 2010
Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1
Year Compared With Historical Placebo
To access this article, please choose from the options below
Conflict of interest: Dr. Nelson B. Watts receives honoraria and consulting fees through the University of Cincinnati Bone Health and Osteoporosis Center and research support from Procter & Gamble Pharmaceuticals and sanofi-aventis. Dr. Jacques P. Brown receives honoraria for lecturing and consultancies as well as grants and research support for clinical trials sponsored by sanofi-aventis Canada and Procter & Gamble Pharmaceuticals. Dr. Gary Cline was an employee of Procter & Gamble Pharmaceuticals. He also owns stock in Procter & Gamble Pharmaceuticals.
PII: S1094-6950(09)00234-0
doi: 10.1016/j.jocd.2009.09.005
© 2010 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Clinical Densitometry
Volume 13, Issue 1
, Pages
56-62
, January 2010
